Background: Antenal indomethacin reportedly decreases the responses of a symptomatic patent ductus arteriosus (sPDA) to postnatal indomethacin treatment. Whether a similar exposure affects the responses to indomethacin prophylaxis is unknown.
Introduction
The incidence of a symptomatic patent ductus arteriosus (sPDA) among extremely low birth weight (ELBW) infants is reported to be 55-70%. 1 This is important because a hemodynamically significant sPDA is associated with a high occurrence of neonatal complications such as congestive heart failure, pulmonary hemorrhage and necrotizing enterocolitis (NEC). 2 Although spontaneous closure of sPDA can occur, the majority of ELBW infants require pharmacological treatment or surgical ligation. 3 The responsiveness of the ductus arteriosus to pharmacological agents, such as indomethacin, provides clinicians with the opportunity for postnatal treatment (early symptomatic) or more recently, for prevention (prophylaxis). 2, 4, 5 Responsiveness of the ductus arteriosus to either mode of management has been good, albeit not universal. Many factors are known to affect sPDA responsiveness both postnatally 6 and more pertinent to this study, antenatally. [7] [8] [9] [10] Indomethacin tocolysis remains valuable in the management of premature labor, but its unavoidable effects on the fetus and the newborn are of concern. [11] [12] [13] Observational studies of infants of p32 weeks of gestation suggest that antenatal indomethacin may decrease the responsiveness of an sPDA to postnatal indomethacin. [7] [8] [9] [10] Whether a similar exposure influences the clinical response to indomethacin prophylaxis remains unknown. Recent studies have shown that the ductus arteriosus in ELBW infants of less than 28 weeks are less responsive to both antenatal and postnatal indomethacin than those of infants of older gestational age (GA). 1, [14] [15] [16] Thus, it is possible that antenatal indomethacin may not affect the ductus arteriosus postnatal responsiveness in ELBW infants. The purpose of this investigation was to evaluate the influence of indomethacin tocolysis on the clinical responsiveness of ductus arteriosus to prophylaxis and that of sPDA to indomethacin treatment in ELBW infants.
Methods
We retrospectively reviewed the medical records of all infants with GA of p28 weeks and birth weights p1000 g born at The Ohio State University Medical Center between July 1999 and June 2006. This investigation was approved by the Institutional Review Board. Fifty-eight ELBW infants whose mothers received indomethacin tocolysis and 58 others whose mothers did not receive antenatal indomethacin, were matched by gender, GA, birth weight, year of birth and by mode of postnatal sPDA management (i.e. indomethacin prophylaxis or early sPDA treatment). Infants with major congenital malformations or with maternal isoimmunization were excluded from this study. In our institution, indomethacin (Indocin IV Merck, WestPoint, PA, USA) is used in patients of no more than 32 weeks of gestation as a tocolytic agent only after magnesium sulfate and/or terbutaline have failed to stop premature labor. Our standard protocol consists of a 50 mg oral dose followed by 25 mg every 6 h for 48 h (cumulative dose of 225 mg). 12 Relative contraindications to postnatal indomethacin use included active bleeding, low platelet count (p60 000/mm 3 ), oliguria (p0.5 ml/kg/h), elevated serum creatinine (X1.5 mg/dl) and active or suspected NEC. The decision to prescribe indomethacin prophylaxis was based on the attending neonatologist's preference. Indomethacin prophylaxis was initiated within 15 h from birth at a dose of 0.1 mg/kg IV (intravenously) over 40 min to be repeated at 24 and 48 h of life.
A ductus arteriosus was considered symptomatic if clinical signs (murmur, wide arterial pulse pressure, hemodynamic or respiratory compromise attributable to PDA) were corroborated with echocardiographic evidence. Indomethacin treatment was started at a dose of 0.2 mg/kg intravenously over 40 min to be repeated at 12 and 24 h. The failure to prevent by prophylaxis or to successfully treat an sPDA prompted a second indomethacin course or a surgical ligation.
GA was determined by first trimester ultrasound, by obstetrical dating of the pregnancy and/or by examination of the infant after birth. Upon admission to the neonatal intensive care unit, all ELBW infants were treated empirically with ampicillin (100 mg/kg/day IV divided in two doses every 12 h) and gentamicin (5 mg/kg/day IV given every 48 h) for 2 days if blood cultures were negative. Mechanical ventilation was performed with a neonatal pressure-limited time-cycled ventilator and, when indicated, with high-frequency ventilation. Umbilical arterial catheterization was performed for blood pressure and blood gas monitoring, and umbilical or central venous catheters were used for long-term parenteral nutrition. Exogenous surfactant (Survanta Ross Products Division, Abbott Laboratories, Columbus, OH, USA) was given at the manufacturer's recommended dosage (4 ml/kg).
Renal function was evaluated by urinary output and by serum creatinine levels. Intraventricular hemorrhage (IVH) was documented by head ultrasound and was graded accordingly. 17 NEC was diagnosed by clinical signs confirmed by the radiographic presence of pneumatosis intestinalis, portal air or free intraperitoneal air. Retinopathy of prematurity (ROP) was staged according to international classifications and was diagnosed by a pediatric ophthalmologist who participated in the NIH CRYO, STOP and ET-ROP investigations. Considering the severity of these morbidities, ROP stages 3-5 were grouped and analyzed together.
Statistical analysis
Comparisons between groups and subgroups of ELBW infants were made with w 2 , Fisher's and t-test. GAs were rounded to the closest completed week (i.e. 23 1/7-23 3/7 became 23 and 23 4/7-23 6/7 became 24 weeks). When applicable, data are presented as mean±s.d.
Results
Our study population consisted of 58 ELBW infants whose mothers received antepartum indomethacin tocolysis and 58 ELBW infants whose mothers did not receive indomethacin. Mothers in these two groups were comparable in demographic, clinical characteristics and ethnic distribution (80% Caucasian, 18% African American and 2% Hispanic). Antepartum complications of pregnancies for the two groups of mothers are shown in Table 1 . Preeclampsia was less common and preterm labor and chorioamnionitis were more common among women who received indomethacin. Antepartum steroids and cesarean delivery occurred with similar frequency in both groups. 
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At the initiation of indomethacin tocolysis, 55 of the 58 (95%) fetuses were p26 weeks of gestation whereas the remaining three (5%) were at 27 weeks. Median duration of tocolysis was 2 days (range 1-5 days), whereas the median time from the last dose to delivery was 1 day (range 1À16 days). Median total indomethacin cumulative dose was 250 mg (range 75-600 mg). Analysis of the time from completion of indomethacin tocolysis to delivery showed that 10% of the patients delivered during the 1st day, 40% delivered between the 2nd and the 5th day and 50% delivered after the 5th day.
Neonatal outcomes
Neonatal outcomes for the 58 infants exposed to antenatal indomethacin and their 58 matched controls are presented in Table 2 . Study and control groups were similar in mean birth weight, and GA. On further analysis, 97% of the study as well as 97% of control infants were born at or before 27 weeks of gestation. Other similarities between study and control infants were low, 1 and 5 min Apgar scores. Dopamine administration for arterial blood pressure control after birth was needed by 14 of 58 (24%) indomethacin-exposed infants and by 16 of 58 (28%) control infants.
During the first day of life, serum creatinines were similar between the two groups (p1.0 mg/dl in 75 and 65%, 1.1-1.4 mg/dl in 22 and 30% and X1.5 mg/dl in 3 and 5% of the study and control infants, respectively). Severe oliguria (<1 ml/kg/h) was noted in four infants (two study and two control).
All ELBW infants received exogenous surfactant at a median dose of 2 (range 1-4), although mechanical ventilation was used in both groups with similar frequency: median duration 20 days (range 1-300 days). NEC developed in 10% study and in 7% control infants. Neonatal deaths occurred in 26% of study and control ELBW infants. Intestinal perforations were noted in 5% of ELBW infants not exposed to antenatal indomethacin.
Normal head ultrasounds combined with Grade I-II IVH were found in 79% study and in 83% control infants. Grades III-IV IVH were seen in 17% and 14% whereas periventricular leukomalacia was observed in 3% of either group. Stage 3-5 ROP was observed in 26% of surviving infants in both groups.
Prevalence and treatment of sPDA following indomethacin prophylaxis Forty-three of 58 (74%) infants in each group received indomethacin prophylaxis. The incidence of sPDA among ELBW infants whose mothers received antenatal indomethacin (17 of 43, 40%) was similar to that of infants whose mothers did not (16 of 43, 37%). Owing to severe oliguria and high serum creatinine, two infants from each group underwent surgical ligation whereas the remaining infants (15 and 14) received postnatal indomethacin treatment at a mean age of 5 and 6 days, respectively. Successful response to indomethacin treatment was observed in seven of 15 (47%) antenatally exposed infants and in four of 14 (29%) control infants. Responders were demographically and clinically similar to non-responders.
Response to indomethacin treatment for symptomatic PDA Fifty-five percent of the 58 antenatally exposed infants and 53% of the control infants developed sPDA and were treated. Owing to severe oliguria and high serum creatinine, two infants from the antenatally indomethacin exposed infants and two control infants underwent surgical ligations whereas the remaining infants received indomethacin treatment at a mean age of 5 and 6 days, respectively (Table 3) .
Successful response to indomethacin treatment was observed in 53% antenatally exposed infants and in 45% controls. Responders were demographically and clinically similar to non-responders.
Clinical response to different maternal indomethacin dose
The cohort of 58 infants exposed to antenatal indomethacin was divided into two subgroups according to the total cumulative indomethacin dose (p225 mg and >225 mg) that their mothers had received (Table 4) . Twenty-eight fetuses were exposed to a mean of 160±61 mg indomethacin whereas the remaining 30 infants were exposed to a mean of 347±101 mg. Duration of the antenatal indomethacin exposure was shorter in the 'low' than in the 'high' cumulative dose group (1.5 vs 3 days, P<0.05), but the time from the last dose to delivery was not significantly different (2 and 3 days, respectively).
ELBW infants in the 'low' and 'high' cumulative dose groups showed similar birth weights and GA at delivery. Neonatal death, incidence of NEC, severe IVHs and severe ROP occurred with similar frequency in both groups (Table 4) . 
Effects of indomethacin tocolysis L Cordero et al
Of the 28 'low' dose-exposed infants, 11 developed sPDA and were treated (seven from the prophylaxis and four from the early sPDA treatment group). Of the 30 'high' dose-exposed infants, 21 developed sPDA and required treatment (10 from the prophylaxis and 11 from the early sPDA treatment group). Two infants from the 'high' dose-exposed group underwent surgical ligation whereas the remaining 11 and the 19 infants from the 'low' dose group received indomethacin treatment at a mean age of 5 and 6 days, respectively. Successful response to indomethacin treatment was observed in 54% of the 'low' dose-exposed infants and in 53% of the infants in the 'high' dose group. Responders were demographically and clinically similar to non-responders.
Discussion
During labor, prostaglandins facilitate myometrial contractions; thus, prostaglandin inhibitors (i.e. indomethacin) have been used as tocolytics since the 1970s. 11 They have been more effective than placebo in delaying delivery for more than 48 h. 12, 13 As indomethacin readily crosses the placenta, it can also inhibit prostaglandin synthesis in fetal tissues creating valid clinical concerns for the fetus and the newborn. 11, 13, 18 Adverse neonatal events have been associated with the prolonged use of antenatal indomethacin, especially in fetuses of 34 weeks of gestation or older. 18 In a recent meta-analysis on the neonatal safety of indomethacin tocolysis, Loe et al. 13 cautiously concluded that before 34 weeks of gestation antenatal indomethacin does not appear to increase adverse neonatal events.
In the majority of our cases, delivery was significantly delayed and more specifically, benefited women with early gestation pregnancies. In our study, women who started tocolysis at 23 weeks received a longer course than those starting at 24 weeks but both groups managed to deliver at about 25 weeks.
Similar to other studies, 11, 13, 16, [19] [20] [21] we found that the neonatal outcomes among antenatally exposed and non-exposed ELBW infants were similar. More importantly, the incidence of adverse neonatal events in our study is similar to that of other populations of comparable GA who had not been exposed to antenatal indomethacin. [22] [23] The goal of indomethacin prophylaxis is to reduce the severity of intracranial hemorrhage and the incidence and severity of sPDA in ELBW infants by facilitating the early and permanent closure of a ductus arteriosus. [1] [2] [3] [4] The physiological mechanism involved in this process are now beginning to be understood. 1, 24, 25 The presence of sPDA in our study represents a combination of failure of the ductus to close and the reopening of a previously closed ductus. Postnatally, many factors are known to influence the temporary or permanent closure of a ductus arteriosus. 6, 25, 26 More pertinent to our study, the antenatal use of indomethacin has been reported to increase the incidence of sPDA and decrease the response to postnatal indomethacin treatment. [7] [8] [9] [10] Thus, it was conceivable that antenatal indomethacin could have also influenced negatively the responses to indomethacin prophylaxis. Our data, however, showed that antenatally indomethacin-exposed and non-exposed infants had a similar incidence of sPDA. The 40% incidence of sPDA reported here is similar to the 37% reported for 47 infants of 24-25 weeks GA who also received prophylaxis. 6 Our results do not agree with the 24% incidence reported in a recent randomized multicenter study. 4 The discrepancy between their results and ours can be explained by the more advanced GA of Effects of indomethacin tocolysis L Cordero et al the infants in the multicenter study (26±2 vs 25±1 weeks, respectively). Among the multiple factors known to decrease the response to postnatal indomethacin, GA and postnatal age at the time of treatment are the most relevant. 1, 2, 26 Satisfactory clinical response to indomethacin treatment of sPDA is expected to be 60% for 28 weeks GA 3 and about 50% for those ELBW infants at 24-25 weeks GA. 6 In the present study, successful indomethacin treatment of sPDA was noted in 16 of 30 (53%) and 13 of 29 (45%) study and control ELBW infants respectively.
Early clinical studies of ELBW infants of up to 32 weeks GA that reported a decrease in the responses of sPDA to postnatal indomethacin treatment [7] [8] [9] [10] were followed by an animal investigation that provided a potential physiopathological explanation. 24 In the fetal lamb, when indomethacin produced a 'marked' degree of ductal constriction in utero, there is vessel remodeling that leads to a significant decline in its contractile capability. 24 In the human, the fetal ductus constricts as early as 24 weeks of GA, but that constriction, independent of indomethacin serum levels, is considered to be 'minimal' at least until 31 weeks. 11, 14 Therefore, it is plausible that a minimal ductus constriction in utero in ELBW infants of p27 weeks of gestation may not allow for the vessel remodeling that renders the ductus unresponsive postnatally. In preterm infants, the ductus frequently fails to develop the level of profound ischemia needed to cause remodeling, thus allowing the ductus to remain open, or if it is already closed to reopen. 1, 25 The incidence of sPDA was higher among infants in the 'high' dose antenatal indomethacin group than in those in the 'low' dose group (70% vs 39%, P ¼ 0.01, respectively). This could be explained by the fact that 11 of the 15 early sPDA treatments were in the 'high' antenatal indomethacin dose groups, whereas only four were in the 'low' dose group. Whether prolonged antenatal indomethacin exposure in ELBW infants is associated with a high incidence of sPDA deserves further study. Nevertheless, the clinical responses to indomethacin prophylaxis and indomethacin treatment reported here were similar. It could be that GA (i.e. p27 weeks) rather than the actual dose or duration of indomethacin is the factor controlling the clinical response of the ductus arteriosus.
In summary, we find that the responsiveness to indomethacin prophylaxis or that of sPDA to postnatal indomethacin is unaffected in a group of ELBW infants exposed to indomethacin tocolysis. The clinical relevance of our study is that clinicians should not disregard the option for postnatal indomethacin treatment after indomethacin tocolysis in ELBW infants whose GA is p27 weeks.
